FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology. What is presented is a method for inhibiting a malignant tumour using nucleic acids encoding p53 elephant or p53 elephant proteins. Also disclosed is a composition containing said nucleic acids or proteins.
EFFECT: invention enables efficient recovery of p53 functions in malignant tumour cells and considerably increases apoptosis of tumour cells.
20 cl, 14 dwg, 3 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ADENOVIRUSES AND METHODS FOR ADENOVIRUS APPLICATION | 2019 |
|
RU2782528C1 |
| MULTIVALENT PD-L1-BINDING COMPOUNDS FOR TREATING MALIGNANT NEOPLASMS | 2020 |
|
RU2816646C2 |
| MONOCLONAL ANTIBODY TO ACTIVATED PROTEIN FROM HUMAN AND PRODUCTION AND USE THEREOF | 2021 |
|
RU2824515C1 |
| INFLUENZA VIRUS CAPABLE OF INFECTING CANINES AND ITS USE | 2020 |
|
RU2802222C2 |
| PROTEINS BINDING NKG2D, CD16 AND TUMOUR-ASSOCIATED ANTIGEN | 2018 |
|
RU2816716C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF MALIGNANT TUMOR | 2019 |
|
RU2781542C2 |
| FUSION PROTEIN OF DCTN1 PROTEIN WITH RET PROTEIN | 2018 |
|
RU2813996C2 |
| PEPTIDES AND THEIR USE IN TREATMENT OF DISEASES, DISORDERS OR CONDITIONS ASSOCIATED WITH MUTANT p53 | 2017 |
|
RU2762089C2 |
| DIRECTED REGENERATION OF BROKEN BONE BY MEANS OF STIMULATION OF PARATHYROID HORMONE RECEPTOR | 2017 |
|
RU2785401C2 |
| IL2 AND MUTANT TNF IMMUNOCONJUGATES | 2017 |
|
RU2758139C2 |
